SGLT2 Inhibitors vs GLP-1 Drugs: Kidney Study Results
SGLT2 inhibitors beat GLP-1 drugs on some kidney outcomes, but mortality and albuminuria complicate the choice. What the first head-to-head study found today.
Tirzepatide and SGLT2 Inhibitors Show an AF Signal
Can tirzepatide and SGLT2 inhibitors reduce atrial fibrillation burden? New data link metabolic therapy to fewer AF procedures, but trials must confirm it.
HFpEF exercise training improves fitness and quality of life, but evidence does not yet show fewer deaths or hospitalizations. Here's what the trials show.